University of Michigan

Tom Sweet elected to 3M Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Education, Certified Public Accountant, NYSE, Strategic planning, PwC, Treasury, University of Michigan, Growth, 3M, Dell, CFO, Western Michigan University, Privatization, Accounting, Telos (company), The Salvation Army, Dell Technologies, Management

ST. PAUL, Minn., Nov. 7, 2023 /PRNewswire/ -- 3M (NYSE: MMM) announced today that Tom Sweet, retired Chief Financial Officer (CFO), Dell Technologies, has been elected to 3M's Board of Directors, effective November 6, 2023.

Key Points: 
  • ST. PAUL, Minn., Nov. 7, 2023 /PRNewswire/ -- 3M (NYSE: MMM) announced today that Tom Sweet, retired Chief Financial Officer (CFO), Dell Technologies, has been elected to 3M's Board of Directors, effective November 6, 2023.
  • In connection with Mr. Sweet's election, the Board of Directors increased its size from 11 to 12 members.
  • Mr. Sweet served as CFO of Dell Technologies from 2014-2023, retiring after 26 years of leadership at the leading enterprise technology company.
  • He serves on the board of directors of Trimble, an industrial technology company, and on the Salvation Army of Central Texas Advisory Board.

New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect

Retrieved on: 
Tuesday, November 7, 2023
Patient, National Comprehensive Cancer Network, Huntsman Cancer Institute, Incidence, Chemotherapy-induced peripheral neuropathy, Biomarker, Vitamin D deficiency, MD, Doctor of Philosophy, Research, Finger, Hypoesthesia, Quality of life, Paclitaxel, The, Risk, CIPN, Doctor of Pharmacy, Sensation, University, Paresthesia, University of Michigan, University of Michigan Rogel Cancer Center, Cancer, Cleveland Clinic, Breast cancer, Neuropathic pain, University of Michigan College of Pharmacy, Peripheral neuropathy, Vitamin D, Dietary supplement, Pharmacy

PLYMOUTH MEETING, Pa., Nov. 7, 2023 /PRNewswire/ -- New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.

Key Points: 
  • The researchers also found that inducing vitamin D deficiency in an accompanying mice model study caused neurotoxicity-like symptoms.
  • "There are barely any negative consequences that come from taking steps to increase vitamin D levels.
  • The researchers also noted that it is well-established that vitamin D deficiency is more common in self-reported Black patients.
  • This research holds the promise of shedding future light on the mechanisms underlying CIPN and the potential identification of biomarkers that could predict CIPN incidence."

Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”

Retrieved on: 
Tuesday, November 7, 2023
Kidney, Chronic kidney disease, EST, Senior, CKD, University of Michigan, Fibrinolysis, University of Erlangen–Nuremberg, University, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical-stage company focused on transforming the treatment of kidney diseases, today announced that management will host a virtual event titled, “Transforming the Treatment Landscape of Chronic Kidney Disease,” (CKD) on November 14, 2023 from 11:00 a.m. to 12:30 p.m. EST.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical-stage company focused on transforming the treatment of kidney diseases, today announced that management will host a virtual event titled, “Transforming the Treatment Landscape of Chronic Kidney Disease,” (CKD) on November 14, 2023 from 11:00 a.m. to 12:30 p.m. EST.
  • The program will include remarks from executive and scientific management relating to Walden’s clinical and preclinical programs, where they are pursuing disease-modifying treatments for kidney diseases.
  • (University of Michigan, Kidney Health Initiative) and Mario Schiffer, M.D.
  • (Friedrich-Alexander-University Erlagen-Nürnberg) to discuss the CKD treatment landscape and the great need for better therapeutic options for this patient population.

Patient Experience Journal, published in association with The Beryl Institute, Releases Volume 10, Issue 3

Retrieved on: 
Tuesday, November 7, 2023
Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Medical University of Vienna, Oregon Health & Science University, Ariel University, Research, Agility, University of California, San Francisco, University, Implementation research, Medical school, University of Alabama, Northwestern Health Sciences University, University of Michigan, Movement, Nursing, Management

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 3 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • "This issue closes the first decade of Patient Experience Journal's (PXJ) contribution to evidence and innovation, to sharing stories and research, to elevating the conversation and pushing the boundaries of the experience movement."
  • said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • "We have never hesitated to nudge at the status quo or to respond with agility to the challenging moments we have faced.
  • We have welcomed diverse voices as contributors, and we have seen an even more diverse readership."

Peter Vanderkaay, Olympic Gold Medalist and Big Blue Swim School Owner, Inducted into Michigan Athletic’s Hall of Honor

Retrieved on: 
Monday, November 6, 2023
Family, Sports, Consumer, Teens, Children, Swimming, Michigan Hall of Justice, World championship, Vanderkaay, Curriculum, University, NCAA, University of Michigan, Conference, IBM, Interior design, Nightclub

Big Blue Swim School , one of the country’s fastest-growing franchises in the $3 billion learn-to-swim industry, proudly announces that one of its owners, Peter Vanderkaay, was inducted into the University of Michigan athletic department’s 2023 Hall of Honor class.

Key Points: 
  • Big Blue Swim School , one of the country’s fastest-growing franchises in the $3 billion learn-to-swim industry, proudly announces that one of its owners, Peter Vanderkaay, was inducted into the University of Michigan athletic department’s 2023 Hall of Honor class.
  • Vanderkaay joined the ownership group behind the Big Blue Swim School in Sterling Heights in 2022.
  • Vanderkaay was introduced to Big Blue Swim School by Chris DeJong, University of Michigan teammate and founder of the swim school.
  • To learn more about Big Blue Swim School, visit https://bigblueswimschool.com .

The Standard Promotes Brad Yoder to Second Vice President of Life and Supplemental Claims

Retrieved on: 
Friday, November 3, 2023
Finance, Professional Services, Technology, Insurance, Software, Yoder, Standard Insurance Company, Policy, The Standard, Retirement, Economics, Eastern Michigan University, State Farm, Multimedia, Brad Yoder, University of Michigan, Standard, Pension, Management, Life

Standard Insurance Company (The Standard) announced today that Brad Yoder has been promoted to second vice president of Life and Supplemental Claims.

Key Points: 
  • Standard Insurance Company (The Standard) announced today that Brad Yoder has been promoted to second vice president of Life and Supplemental Claims.
  • View the full release here: https://www.businesswire.com/news/home/20231103790164/en/
    Brad Yoder, second vice president of Life and Supplemental Claims at The Standard.
  • In his most recent position as senior director of Life and Supplemental Claims, he led the creation of a dedicated Supplemental Claims team earlier this year.
  • “Brad is a proven leader with extensive experience across many areas at The Standard,” said Jeanne Ryan, vice president and head of Claims at The Standard.

Dynami Funds New Groundbreaking Research for Lobular Breast Cancer

Retrieved on: 
Wednesday, November 1, 2023
Dean (education), Karmanos Cancer Institute, Biomarker, Leigh, Doctor of Philosophy, Disease, Risk, Partnership, DRS, University of Michigan, UPMC, Fertility preservation, Hope, Physician, Hereditary lobular breast cancer, Impact, University of Pittsburgh Medical Center, IVF, Breast cancer, University, Morávek, Cancer, Patient, Biomedical engineering, ILC, University of Colorado, History, MD, Work, Woman, University of Colorado School of Medicine, Black, Multimedia, Recurrence, Personalized medicine, United States and Canadian Academy of Pathology, Medical device, Vaccine, Medical imaging, Birth control, Pharmaceutical industry, Research, Pathology, Pharmacology, Dynamy

DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health. Recently released University of Michigan Health Impact Report outlines the progress and work made possible by the Dynami Foundation's initiatives that are focused on transforming the future of invasive lobular breast cancer (ILC) through the funding of research.

Key Points: 
  • DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health.
  • From groundbreaking new research on circulating cells to a dual-institution effort to combat cancer, Dynami and University of Michigan have partnered to drive progress.
  • A patient-centered decision-making process by understanding goals of lobular breast cancer patients for an elevated, personalized breast reconstruction experience led by Dr. Paige Myers.
  • Dynami has funded over 12 research projects and will continue to fight for advancement for lobular breast cancer just like the incredible work and impact that we've made here."

Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan's Dr. Erin Cobain

Retrieved on: 
Tuesday, October 31, 2023
Principal, MP2, Breast, NCI, MP, HER2, MD, PCR, SWOG, Doctor of Philosophy, National Cancer Institute, Clinical trial, Neoplasm, NSC, Breast cancer, Recurrence, Immunotherapy, University, HR, Gene, Wright Axcess-Ultralow, Woman, Cancer, University of Michigan, Patient, Gene expression profiling, Birth control, Pharmaceutical industry, Health, MammaPrint

IRVINE, Calif. and AMSTERDAM, Oct. 31, 2023 /PRNewswire/ -- Agendia, Inc., a global leader in innovative genomic technology and diagnostic tests, is collaborating with National Cancer Institute (NCI), part of the National institutes of Health and SWOG Cancer Research Network, funded by NCI, for a new clinical trial that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.

Key Points: 
  • SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
  • This trial is sponsored by NCI and led by SWOG with participation of the National Clinical Trials Network (NCTN).
  • Dr. Erin Cobain, MD, University of Michigan, will be the Principal Investigator of S2206.
  • Also collaborating on the study is Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center, who serves as the SWOG Breast Cancer Committee Chair.

James Beard Chefs, Global Sommeliers, and Art Community Join for Breast Cancer Awareness

Retrieved on: 
Wednesday, October 25, 2023
Paragon, Cure, System, Heart, ILC, Family, Hereditary lobular breast cancer, Impact, Research, Friends, Recurrence, Breast cancer, University, University of Michigan, Communication, Santi Sergio e Bacco, Birth control

DETROIT, Oct. 25, 2023 /PRNewswire/ -- The Dynami Foundation has curated a list of trailblazing culture makers to join together for Breast Cancer Awareness in Detroit. In its 8th year, the foundation's Uncork for a Cure event is bringing together the healing power of art and food to curate pieces of work and provide sustenance for a cause. The fundraising event has raised over two million dollars over the years and impacted groundbreaking new research in support of lobular breast cancer through their partnership with University of Michigan's Rogel Cancer Center, University of PIttsburgh Medical Center, University of Colorado, and Karmanos Cancer Institute.

Key Points: 
  • Artwork curated by Mary Wysocki of Paragon Art Collective will be unveiled at the event from local and international artists.
  • Mike Han–whose mother and grandmother are breast cancer survivors–will be back for another year auctioning off a piece of his work in honor of breast cancer awareness.
  • Local artists Eric "El Cappy" Lowry, Amelia Currier, Takeisha Jefferson, and others will join Mike Han to support the research and awareness for lobular breast cancer.
  • They are standing with me as partners to raise awareness, and bring our community together, to fight for a cure," says Dynami founder and breast cancer survivor, Flora Migyanka.

Feinstein Institutes Awarded $6.1M to Fund Bipolar Disorder Patient and Research Hub

Retrieved on: 
Thursday, October 19, 2023
Mental Health, Health, Biometrics, Clinical Trials, Research, Science, Biotechnology, Knowledge, Patient, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Medical research, Feinstein, Feinstein Institutes for Medical Research, Transcranial magnetic stimulation, Johns Hopkins University, Zucker Hillside Hospital, Hofstra University, Psychiatry, Bipolar disorder, Multimedia, Donald, Clinical trial, Schizophrenia, Institutional review board, Behavioural sciences, Credit, University, Magnetic resonance imaging, University of California, Los Angeles, BD2, University of Michigan, Hospital, BSN, Mayo Clinic, Pharmaceutical industry, MD, Brigham, Wellcome

Approximately 2.3 million Americans live with bipolar disorder who are impacted by dramatic shifts in mood, energy and activity levels.

Key Points: 
  • Approximately 2.3 million Americans live with bipolar disorder who are impacted by dramatic shifts in mood, energy and activity levels.
  • Through a national research grant and innovative networking system aimed to connect patients to care, it might become easier for people with bipolar disorder to find new treatments and clinical trials.
  • (Credit: Feinstein Institutes)
    Researchers at The Feinstein Institutes for Medical Research received a $6.1 million grant from Breakthrough Discoveries for Thriving with Bipolar Disorders Foundation (BD2) to serve as a hub of six other sites across the country.
  • “Although bipolar disorder impacts millions of Americans every year, it is under-researched,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research.